Because dasatinib is already cleared for clinical use, researchers hope that progress can be made more quickly towards trialling the drug in humans as a treatment for DMD.
In contrast, because of the high incidence of TP53 mutations in the HPV - inactive class, these tumors may be less responsive to the standard cisplatin chemotherapy and more sensitive to other chemotherapies such as dasatinib.»
Several targeted drugs (e.g., imatinib [Gleevec ®], dasatinib [Sprycel ®]-RRB- are effective for treating CML because they attack cells with the Philadelphia chromosome, the genetic abnormality that is the hallmark of this type of leukemia.